Melatonin Dosing Recommendations
For adults with delayed sleep-wake phase disorder or insomnia, use 5 mg of melatonin taken 1.5-2 hours before desired bedtime; for elderly patients (≥55 years), use prolonged-release melatonin 2 mg taken 1-2 hours before bedtime; for children and adolescents, use 0.15 mg/kg (maximum 3-5 mg depending on comorbidities) taken 1.5-2 hours before bedtime. 1, 2
Adult Dosing (Ages 18-54)
The American Academy of Sleep Medicine guidelines provide the strongest evidence for adult dosing:
- Standard dose: 5 mg taken between 19:00-21:00 (7-9 PM), administered 1.5-2 hours before desired bedtime
- Duration: Effective for at least 28 days of treatment
- Evidence quality: LOW, but clinically accepted versus no treatment 1
Recent dose-response meta-analysis suggests that 4 mg/day represents the optimal dose, with efficacy peaking at this level for both reducing sleep onset latency and increasing total sleep time. Administration should occur 3 hours before desired bedtime for maximum efficacy 3. This timing is more effective than the commonly used 30-minute window.
Elderly Patients (≥55 Years)
Prolonged-release melatonin 2 mg is the evidence-based choice for elderly patients, taken 1-2 hours before bedtime 2, 4:
- This formulation mimics natural melatonin secretion patterns
- Approved in the EU for patients ≥55 years with primary insomnia
- Treatment duration: up to 13 weeks initially, with studies supporting up to 6 months
- Key advantage: No impairment of psychomotor function, memory, or driving skills the next morning (unlike benzodiazepines)
The evidence for elderly patients shows:
- Sleep latency reduction of approximately 8.9 minutes (though below clinical significance threshold)
- Improved sleep quality and morning alertness
- Better health-related quality of life
- No dependence, tolerance, rebound insomnia, or withdrawal symptoms 4
Important caveat: Higher doses (5-10 mg) have not shown superior efficacy in elderly patients and may increase side effects 5, 6. The 2 mg prolonged-release formulation remains the standard.
Pediatric Dosing
Children/Adolescents WITHOUT Comorbidities (Ages 6-12)
Dose: 0.15 mg/kg (mean dose approximately 4.4 mg), taken 1.5-2 hours before habitual bedtime 1:
- This represents MODERATE quality evidence
- Lower doses (0.05 mg/kg or 0.1 mg/kg) were less effective
- Treatment duration: Effective within 6 nights
- Critical point: Requires informed consent from patient and caregiver due to limited long-term safety data in pediatrics
Children/Adolescents WITH Psychiatric Comorbidities (Ages 6-12)
Dose: Weight-based dosing 1:
- < 40 kg: 3 mg fast-release melatonin
- > 40 kg: 5 mg fast-release melatonin
- Timing: 18:00-19:00 (6-7 PM)
- Duration: 4 weeks minimum
Evidence quality is LOW but shows:
- Advance in dim light melatonin onset (DLMO) by approximately 54 minutes
- Sleep onset time advanced by approximately 37 minutes
- Particularly studied in children with ADHD
Special Pediatric Populations
Autism Spectrum Disorder 7:
- Start with 1 mg fast-release melatonin
- Maximum dose: 4 mg
- Timing: 30-40 minutes before bedtime
- Can escalate by 1 mg every 2 weeks if no response (up to 6 mg maximum)
- 60% of children showed improved sleep with some adverse effects (morning sleepiness)
Alternative dosing for sleep promotion effects 8:
- To advance bedtime: 0.5 mg given 3-4 hours before bedtime
- For sedating effect:
- Infants: 1 mg
- Older children: 2.5-3 mg
- Adolescents: 5 mg
- All given 30 minutes before bed
Timing Optimization
The evidence strongly suggests that timing matters more than previously recognized:
- For circadian phase advancement: Administer 3 hours before desired bedtime 3
- For sleep promotion: Administer 1.5-2 hours before bedtime 1
- Standard clinical practice (30 minutes before bed) appears less optimal than earlier administration 9, 3
Hospital/institutional settings: Consider 18:00 (6 PM) administration for patients with bedtime resistance or circadian disruption 9
Contraindications and Safety Considerations
Relative contraindications:
- Pregnancy and lactation (insufficient safety data)
- Autoimmune disorders (theoretical concern about immune modulation)
- Seizure disorders (limited data, use with caution)
Important safety notes:
- Short-term adverse effects are minimal and resolve upon discontinuation 1, 10
- Most common side effects: drowsiness (28.8%), headache (25.1%) 11
- Long-term safety data in children/adolescents is lacking - this is a critical gap requiring informed consent 1, 10
- No serious adverse reactions have been consistently documented in short-term use
- Quality control issue: In the U.S., melatonin is unregulated as a dietary supplement, with actual content varying widely from labeled doses 10, 11
Clinical Pitfalls to Avoid
Don't use antihistamines as first-line: Despite common practice, antihistamines show minimal benefit for sleep in children with eczema and other conditions, with tolerance developing to sedative effects 8
Don't assume higher doses are better: Evidence shows efficacy plateaus at 4-5 mg in adults and 0.15 mg/kg in children 1, 5, 3
Don't administer too close to bedtime: The common practice of 30-minute pre-bedtime dosing is suboptimal; 1.5-3 hours before bedtime is more effective 9, 3
Don't overlook formulation: Prolonged-release is specifically indicated for elderly patients; fast-release for children with psychiatric comorbidities 1, 2, 4
Don't forget sleep hygiene: Melatonin should complement, not replace, behavioral interventions and sleep hygiene practices 12, 1